HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gundimeda, U. Articles by Gopalakrishna, R. Search for Related Content PubMed PubMed Citation Articles by Gundimeda, U. Articles by Gopalakrishna, R. Social Bookmarking                      What's this?

Volume 271, Number 23, Issue of June 7, 1996 pp. 13504-13514
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Tamoxifen Modulates Protein Kinase C via Oxidative Stress in Estrogen Receptor-negative Breast Cancer Cells

(Received for publication, October 11, 1995, and in revised form, March 22, 1996)

From the Department of Cell and Neurobiology, School of Medicine, University of Southern California, Los Angeles, California 90033

Nonsteroidal agent tamoxifen (Tam), a therapeutic/chemopreventive agent for breast cancer, inhibits protein kinase C (PKC), which is considered to be one of its extra-estrogen receptor sites of action. This drug is required at higher (>100 µM) concentrations to inhibit PKC in the test tube, whereas it is required at lower (1-10 µM) concentrations to induce inhibition of cell growth in estrogen receptor-negative cell types. To identify additional mechanisms of action of Tam on PKC and cell growth, studies with MDA-MB-231, an estrogen receptor-negative breast carcinoma cell type, have been carried out. Upon treatment with 5-20 µM Tam, a cytosol to membrane translocation of PKC occurred within 30 min, which was then followed by a down-regulation of the enzyme within 2 h. A transient generation of Ca²⁺/lipid-independent activated form of PKC was observed during this period. Rapidly growing cells require nearly 2-3-fold lower concentrations (2-5 µM) of Tam than do confluent cells to induce changes in PKC. Furthermore, phorbol ester binding observed with intact cells also decreased in Tam-treated cells only under the conditions PKC was inactivated. Unlike phorbol esters, Tam did not directly support the membrane association of PKC. The release of arachidonic acid correlated with the PKC membrane translocation. Studies carried out with [³H]Tam revealed that Tam partitioned into the membrane, and there was no appreciable covalent association of [³H]Tam with cellular proteins within this limited time period (2 h). Various antioxidants (vitamin E, vitamin C, -carotene, catalase, and superoxide dismutase) inhibited all these cellular effects of Tam. Moreover, vitamin E strikingly blocked Tam-induced growth inhibition. To determine whether oxymetabolites of Tam can affect PKC permanently, OH-Tam was tested with purified PKC. In contrast to Tam, which reversibly inhibited PKC, OH-Tam permanently inactivated the enzyme by modifying the catalytic domain at lower concentrations. The vicinal thiols present within this domain were found to be required to induce this inactivation. This effect was partially blocked by various antioxidants. This is the first report showing the role of oxidative stress in mediating the actions of Tam. Taken together these results suggest that Tam, by initially partitioning into the membranes, induces a generation of transmembrane signals and an oxidative stress to elicit the membrane association of PKC, followed by an irreversible activation, and subsequent down-regulation of this enzyme, which, in part, may lead to cell growth inhibition.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. Shkreta, U. Froehlich, E. R. Paquet, J. Toutant, S. A. Elela, and B. Chabot Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes Mol. Cancer Ther., June 1, 2008; 7(6): 1398 - 1409. [Abstract] [Full Text] [PDF]

				S. M Dougherty, W. Mazhawidza, A. R Bohn, K. A Robinson, K. A Mattingly, K. A Blankenship, M. O Huff, W. G McGregor, and C. M Klinge Gender difference in the activity but not expression of estrogen receptors {alpha} and {beta} in human lung adenocarcinoma cells. Endocr. Relat. Cancer, March 1, 2006; 13(1): 113 - 134. [Abstract] [Full Text] [PDF]

				M. Gago-Dominguez, J. E. Castelao, M. C. Pike, A. Sevanian, and R. W. Haile Role of Lipid Peroxidation in the Epidemiology and Prevention of Breast Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2005; 14(12): 2829 - 2839. [Abstract] [Full Text] [PDF]

				O. Vitseva, D. A. Flockhart, Y. Jin, S. Varghese, and J. E. Freedman The Effects of Tamoxifen and Its Metabolites on Platelet Function and Release of Reactive Oxygen Intermediates J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1144 - 1150. [Abstract] [Full Text] [PDF]

				A.M. Petrunkina, R.A.P. Harrison, M. Ekhlasi-Hundrieser, and E. Topfer-Petersen Role of volume-stimulated osmolyte and anion channels in volume regulation by mammalian sperm Mol. Hum. Reprod., November 1, 2004; 10(11): 815 - 823. [Abstract] [Full Text] [PDF]

				B. Kedjouar, P. de Medina, M. Oulad-Abdelghani, B. Payre, S. Silvente-Poirot, G. Favre, J.-C. Faye, and M. Poirot Molecular Characterization of the Microsomal Tamoxifen Binding Site J. Biol. Chem., August 6, 2004; 279(32): 34048 - 34061. [Abstract] [Full Text] [PDF]

				S. Mabuchi, M. Ohmichi, A. Kimura, Y. Ikebuchi, K. Hisamoto, E. Arimoto-Ishida, Y. Nishio, K. Takahashi, K. Tasaka, and Y. Murata Tamoxifen Inhibits Cell Proliferation via Mitogen-Activated Protein Kinase Cascades in Human Ovarian Cancer Cell Lines in a Manner Not Dependent on the Expression of Estrogen Receptor or the Sensitivity to Cisplatin Endocrinology, March 1, 2004; 145(3): 1302 - 1313. [Abstract] [Full Text] [PDF]

				R. Gopalakrishna and U. Gundimeda Antioxidant Regulation of Protein Kinase C in Cancer Prevention J. Nutr., December 1, 2002; 132(12): 3819S - 3823. [Abstract] [Full Text] [PDF]

				M. Obrero, D. V. Yu, and D. J. Shapiro Estrogen Receptor-dependent and Estrogen Receptor-independent Pathways for Tamoxifen and 4-Hydroxytamoxifen-induced Programmed Cell Death J. Biol. Chem., November 15, 2002; 277(47): 45695 - 45703. [Abstract] [Full Text] [PDF]

				A. B. da Rocha, D.R.A. Mans, A. Regner, and G. Schwartsmann Targeting Protein Kinase C: New Therapeutic Opportunities Against High-Grade Malignant Gliomas? Oncologist, February 1, 2002; 7(1): 17 - 33. [Abstract] [Full Text] [PDF]

				S. M. Swain Tamoxifen for Patients With Estrogen Receptor-Negative Breast Cancer J. Clin. Oncol., September 15, 2001; 19(90001): 93s - 97. [Full Text] [PDF]

				R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72. [Abstract] [Full Text] [PDF]

				E. Speir, Z.-X. Yu, K. Takeda, V. J. Ferrans, and R. O. Cannon III Antioxidant Effect of Estrogen on Cytomegalovirus-Induced Gene Expression in Coronary Artery Smooth Muscle Cells Circulation, December 12, 2000; 102(24): 2990 - 2996. [Abstract] [Full Text] [PDF]

				R. Schiff, P. Reddy, M. Ahotupa, E. Coronado-Heinsohn, M. Grim, S. G. Hilsenbeck, R. Lawrence, S. Deneke, R. Herrera, G. C. Chamness, et al. Oxidative Stress and AP-1 Activity in Tamoxifen-Resistant Breast Tumors In Vivo J Natl Cancer Inst, December 6, 2000; 92(23): 1926 - 1934. [Abstract] [Full Text] [PDF]

				S. Mandlekar, R. Yu, T.-H. Tan, and A.-N. T. Kong Activation of Caspase-3 and c-Jun NH2-terminal Kinase-1 Signaling Pathways in Tamoxifen-induced Apoptosis of Human Breast Cancer Cells Cancer Res., November 1, 2000; 60(21): 5995 - 6000. [Abstract] [Full Text]

				K. R. Hoyt, B. A. McLaughlin, D. S. Higgins Jr., and I. J. Reynolds Inhibition of Glutamate-Induced Mitochondrial Depolarization by Tamoxifen in Cultured Neurons J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 480 - 486. [Abstract] [Full Text]

				M.-H. Delmotte, A. Tahayato, P. Formstecher, and P. Lefebvre Serine 157, a Retinoic Acid Receptor alpha Residue Phosphorylated by Protein Kinase C in Vitro, Is Involved in RXR{middle dot}RARalpha Heterodimerization and Transcriptional Activity J. Biol. Chem., December 31, 1999; 274(53): 38225 - 38231. [Abstract] [Full Text] [PDF]

				I. Suzuma, M. Mandai, H. Takagi, K. Suzuma, A. Otani, H. Oh, K. Kobayashi, and Y. Honda 17 {beta}-Estradiol Increases VEGF Receptor-2 and Promotes DNA Synthesis in Retinal Microvascular Endothelial Cells Invest. Ophthalmol. Vis. Sci., August 1, 1999; 40(9): 2122 - 2129. [Abstract] [Full Text] [PDF]